SAKK/Astellas & AstraZeneca GU-Oncology Research Award
Translational research in GU oncology is important. By translating scientific knowledge into practical solutions, this research improves patient outcomes and enhances treatment strategies. This award supports projects in this research field.
SAKK's GU-Oncology Research Award is funded by Astellas & AstraZeneca and aims to translating basic research discoveries into the clinic. The grant is worth CHF 10 000.
Eligible Projects
Projects should be translational in nature. That is, they should be aimed at translating basic research discoveries into the clinic. Possible projects could include, but are not limited to:
- Development of novel treatments for prostate cancer focused on small molecules, biologics, or radioligand therapies
- Development of diagnostic modalities for GU cancers
- Development of novel prevention strategies for GU cancers
- Approaches can include preclinical, animal, human tissue, and/or human studies
- Purely basic research projects are out of scope
- Must be conducted in Switzerland but can be part of larger collaborative projects. In the case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect. Only costs that are still occurring can be covered by the award.
- Be written in English language
- The abstract of not more than 300 words should include a project title, the rationale, aim of the project, and how this research will be translated into the clinic
Eligible Applicants
Applicants must have a primary place of work in Switzerland and can include graduate or postgraduate researchers or physician-scientists.
Applications that do not fulfill all of the above-mentioned requirements cannot be considered.
Submissions: Applications have to be submitted electronically via SAKK to events@sakk.ch.
Application deadline: September 30, 2024
For further information please refer to the documents below.
In collaboration with 
